Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization

Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surge in in vitro fertilization.


Yanping Kuang, M.D., Qiuju Chen, Ph.D., Yonglun Fu, M.D., Yun Wang, M.D., Qingqing Hong, M.D., Qifeng Lyu, Ph.D., Ai Ai, M.D., Zeev Shoham, M.D.

Volume 104, Issue 1, Pages 62–70



To investigate the use of medroxyprogesterone acetate (MPA) to prevent LH surge during controlled ovarian hyperstimulation (COH) and to compare cycle characteristics and pregnancy outcomes in subsequently frozen-thawed ET (FET) cycles.


A prospective controlled study.


Tertiary-care academic medical center.


Three hundred patients undergoing IVF/intracytoplasmic sperm injection treatment.


In the study group, hMG and MPA were administered simultaneously beginning on cycle day 3. Ovulation was induced with a GnRH agonist or cotriggered by a GnRH agonist and hCG when dominant follicles matured. A short protocol was used in the control group. Viable embryos were cryopreserved for later transfer in both protocols.

Main Outcome Measure(s):

The primary outcome measure was the number of oocytes retrieved. Secondary outcomes included the number of mature oocytes, the incidence of premature LH surge, and clinical pregnancy outcomes from FETs.


The number of oocytes retrieved in the study group was similar to those in the controls (9.9 ± 6.7 vs. 9.0 ± 6.0), and higher doses of hMG were administered. In the study group, LH suppression persisted during ovarian stimulation, and the incidence of premature LH surge was 0.7% (1/150). No statistically significant differences were found in the clinical pregnancy rates (47.8% vs. 43.3%), implantation rates (31.9% vs. 27.7%), and live-birth rates (42.6% vs. 35.5%) in the study group and controls.


The results show that MPA is an effective oral alternative for the prevention of premature LH surge in woman undergoing COH. This finding will help establish a new regimen for ovarian stimulation in combination with embryo cryopreservation.

Clinical Trial Registration Number:


Read the full text at: